pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,732 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1178Endpoints898BioPharma Dive345BioSpace312Fierce Biotech294onclive165raps106globenewswire health73
therapy area
allOncology7642Rare Disease1876Cardiology1743Immunology1482Hematology1323Vaccines1200Pulmonology
  • Abridge secures strategic investment from Eli Lilly and partners with Nvidia on AI foundation model
    Abridge, a health‑tech AI company, announced two new deals on Thursday in New York. Eli Lilly will make a strategic investment in Abridge, signaling pharma interest in AI scribes that document vis…
    STAT · 2mo agoDealPositive↗ source
  • Camurus receives second complete response letter for acromegaly drug CAM2029; Teva announces workforce reductions
    Camurus reported that the FDA issued a second complete response letter for its investigational acromegaly therapy CAM2029, citing issues related to a third‑party manufacturer. The agency’s concern…
    Endpoints · 2mo agoCRLNegative↗ source
← prev
page 73 of 110
next →
fda recalls70
fda medwatch60
fda press38
1192
Psychiatry & CNS866
Ophthalmology497
Pain480
Endocrinology & Metabolism474
Infectious Disease444
  • Some U.S. Employers Plan to End GLP-1 Obesity Drug Coverage in 2027, Even as Prices Fall
    A Reuters report says roughly 10% of U.S. employers that currently cover GLP-1 medicines for weight loss intend to stop covering them in 2027. The move comes as enrollment in obesity-treating drugs…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Neion Bio secures $23M Series A to develop egg-based protein platform for biologics
    Neion Bio announced it closed a $23 million Series A round that was oversubscribed. The funding will be used to advance its platform that leverages chicken eggs, extracting primordial germ cells f…
    Endpoints · 3mo agoDealPositive↗ source
  • AMA and lawmakers challenge insurer AI denial practices, call for oversight
    The American Medical Association and several members of Congress are publicly opposing recent denials of care that rely on artificial‑intelligence algorithms used by insurers. The Department of He…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Nonprofit Blood Cancer United purchases remaining Luvelta supplies to keep compassionate access for children
    Blood Cancer United, formerly the Leukemia & Lymphoma Society, announced it will purchase the remaining inventory of Luvelta, an investigational antibody‑drug conjugate that had been discontinued.…
    STAT · 2mo agoDealPositive↗ source
  • Study finds socioeconomic status drives brain development differences in 9- and 10-year-olds
    Researchers at Washington University School of Medicine examined brain MRI scans from almost 12,000 children who were nine or ten years old. The analysis showed that a child's socioeconomic backgr…
    STAT · 2mo agoNeutral↗ source
  • Medicare Advantage insurers often reverse denied claims on appeal, sparking concerns over care barriers
    STAT's D.C. Diagnosis newsletter reports a troubling pattern in Medicare Advantage plans where initial claim denials are frequently reversed after an appeal. The analysis highlights that most large…
    STAT · 2mo agoRegulatoryNegative↗ source
  • CDC report finds rise in alcohol use among pregnant women since 2020
    A new CDC analysis shows that the proportion of pregnant adults who reported drinking in the past month increased after 2020. The survey data indicate that about 15% of pregnant women reported cur…
    STAT · 2mo agoNegative↗ source
  • Sensorion halts development of SENS-501 for OTOF-related hearing loss after strategic review
    Sensorion announced it is ending the development of its SENS-501 candidate, which was aimed at treating OTOF-related hearing loss, following a strategic review of its pipeline. The biotech said it…
    Endpoints · 2mo agoNeutral↗ source
  • Biopharma’s top scientists and doctors earned eight-figure pay in 2025, still far below CEO salaries
    Endpoints News released a compensation report that ranks the ten highest-paid scientists and doctors in biopharma for 2025. The list shows that several executives received eight-figure total compe…
    Endpoints · 2mo agoNeutral↗ source
  • HHS gives measured response to alcohol risk study as health news roundup covers soda link, NIH debate, diabetes apology and DOJ lawsuit
    The Department of Health and Human Services issued a cautious reaction to a recent paper that examined the relationship between alcohol consumption and health risks, noting the need for further evi…
    STAT · 2mo agoNeutral↗ source
  • NIH mulls grant cap to broaden funding across universities
    NIH officials are evaluating a proposal that would limit the number of research grants any single investigator can receive. The goal is to spread federal funding more evenly across institutions. R…
    STAT · 3mo agoRegulatoryPositive↗ source
  • HHS Secretary RFK Jr. says his calendar is public, but STAT finds no record after a year of requests
    Health secretary Robert F. Kennedy Jr. told reporters his calendar is publicly available as proof of his “radical transparency” pledge. STAT has filed Freedom of Information Act requests and email…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Open-access fees rise to $12,850 for NIH-funded study in Nature Medicine
    In 2025 a randomized clinical trial led by Elizabeth Selvin was published in Nature Medicine without any publication charge. The paper underwent peer review and editorial processing at no cost to t…
    STAT · 3mo agoNegative↗ source
  • Parabilis Medicines raises $670 million in record-setting biotech IPO on Nasdaq
    Parabilis Medicines, a Cambridge, Massachusetts drug developer, completed its initial public offering on Nasdaq, raising $670 million. The offering is described as the largest biotech IPO in indus…
    Endpoints · 3mo agoDealPositive↗ source
  • Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development
    Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…
    Endpoints · 3mo agoDealPositive↗ source
  • US judge upholds law to curb hospital drug prices as shortage trends show mixed signals
    A federal judge in Washington rejected a pharmaceutical industry challenge to a state law aimed at lowering hospital drug prices, leaving the pricing reforms in place. Data from a recent analysis…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Europe’s drug pricing split: UK leans pro‑industry while Germany eyes cuts and higher fees
    European nations are feeling mounting pressure to rein in drug prices, a trend that is reshaping the market for both manufacturers and patients across the continent. In the United Kingdom, lobbyin…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA review
    Beren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…
    Endpoints · 3mo agoDealPositive↗ source
  • Novartis inks second molecular glue partnership with Orionis, $40M upfront
    Novartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…
    Endpoints · 3mo agoDealPositive↗ source
  • SonoThera secures $125 million to advance ultrasound-based gene therapy for Duchenne and polycystic kidney disease
    SonoThera announced it has raised $125 million in financing to move its ultrasound-based non-viral gene therapy platform toward clinical testing. The funding will support the company’s two lead pr…
    Endpoints · 3mo agoDealPositive↗ source
  • Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debate
    Sanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…
    STAT · 3mo agoNeutral↗ source
  • Shattuck Labs raises $75M in public offering, selling 10.5M shares at $4 each
    Shattuck Labs announced a $75 million public offering to raise capital. The company is selling more than 10.5 million shares at $4 per share and is also issuing pre‑funded warrants to selected inv…
    Endpoints · 3mo agoDealNeutral↗ source
  • Biotech executives pocket nearly $1 billion in M&A golden parachutes, 12 receive $35M+ payouts
    An Endpoints News analysis identified a group of twelve biotech leaders who collectively earned close to $1 billion in exit compensation after selling their companies. Each of these executives sec…
    Endpoints · 3mo agoNegative↗ source